CA
KYMR icon

Clearstead Advisors’s Kymera Therapeutics KYMR Stock Holding History

Clearstead Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230 Buy
+2
New +$172 ﹤0.01% 3167

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Clearstead Advisors's KYMR Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 2 shares worth $230. The stake represents ﹤0.01% of the portfolio and ranks #3167 among its holdings.

275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Clearstead Advisors held 2 shares of Kymera Therapeutics worth $230 as of Q2 2026.
  • Kymera Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3167 holding.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.